Polygenic risk scores in major depressive disorder: A systematic review across diagnostic, treatment, course/severity, and subtype domains.
J Affect DisordJul 31, 2026 (epub)
Clinical ResearchPsychiatry
Yang Li, Rui Liu, Yijing Guo et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined the role of polygenic risk scores (PRS) in major depressive disorder (MDD) across various domains, including diagnosis and treatment. Analyzing 60 studies, the review found that all 10 studies on MDD-derived PRSs indicated higher liability in cases (p = 0.002). However, treatment-related findings were mostly null or mixed.
Key findings
- 44 out of 56 diagnostic records showed positive findings for PRS in MDD.
- 14 out of 18 studies indicated positive findings for overall depressive symptom severity.
- Pharmacological response findings were mostly null, with 10 positive and 18 null results.
- Treatment-resistant depression findings varied significantly by operational definition.
Why it matters
Understanding the genetic underpinnings of major depressive disorder through polygenic risk scores can enhance diagnostic accuracy and inform treatment strategies. However, the variability in findings highlights the need for standardized approaches in future research.